CA2881389C - Methods and kits for screening patients with a cancer - Google Patents

Methods and kits for screening patients with a cancer Download PDF

Info

Publication number
CA2881389C
CA2881389C CA2881389A CA2881389A CA2881389C CA 2881389 C CA2881389 C CA 2881389C CA 2881389 A CA2881389 A CA 2881389A CA 2881389 A CA2881389 A CA 2881389A CA 2881389 C CA2881389 C CA 2881389C
Authority
CA
Canada
Prior art keywords
cancer
patient
predetermined reference
patients
expression level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2881389A
Other languages
English (en)
French (fr)
Other versions
CA2881389A1 (en
Inventor
Jerome Galon
Franck Pages
Bernhard Mlecnik
Gabriela BINDEA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé et de la Recherche Médicale
Université Paris Cité
Original Assignee
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé et de la Recherche Médicale
Universite de Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique - Hôpitaux de Paris, Institut National de la Santé et de la Recherche Médicale, Universite de Paris filed Critical Assistance Publique - Hôpitaux de Paris
Publication of CA2881389A1 publication Critical patent/CA2881389A1/en
Application granted granted Critical
Publication of CA2881389C publication Critical patent/CA2881389C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
CA2881389A 2012-08-06 2013-08-05 Methods and kits for screening patients with a cancer Active CA2881389C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305975.0 2012-08-06
EP12305975 2012-08-06
PCT/EP2013/066425 WO2014023706A1 (en) 2012-08-06 2013-08-05 Methods and kits for screening patients with a cancer

Publications (2)

Publication Number Publication Date
CA2881389A1 CA2881389A1 (en) 2014-02-13
CA2881389C true CA2881389C (en) 2022-01-04

Family

ID=46762994

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2881389A Active CA2881389C (en) 2012-08-06 2013-08-05 Methods and kits for screening patients with a cancer

Country Status (13)

Country Link
US (2) US20150218650A1 (enExample)
EP (2) EP2880180B1 (enExample)
JP (2) JP6559566B2 (enExample)
AU (1) AU2013301609B2 (enExample)
CA (1) CA2881389C (enExample)
DK (1) DK2880180T3 (enExample)
ES (1) ES2702722T3 (enExample)
LT (1) LT2880180T (enExample)
PL (1) PL2880180T3 (enExample)
PT (1) PT2880180T (enExample)
SG (1) SG11201500922RA (enExample)
TR (1) TR201819211T4 (enExample)
WO (1) WO2014023706A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
SG10202005315SA (en) * 2014-08-19 2020-07-29 Nat Univ Corporation Okayama Univ Agent for treating and/or preventing diseases associated with immune abnormalities by combining biguanide antidiabetic drug with immunosuppressive factor blocking agent or costimulatory receptor agonist
EP3240908A2 (en) * 2014-12-30 2017-11-08 F. Hoffmann-La Roche AG Methods and compositions for prognosis and treatment of cancers
JP7281903B2 (ja) * 2016-05-09 2023-05-26 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） 固形腫瘍を有する患者をクラス分けするための方法
MX2019010295A (es) 2017-03-01 2019-11-21 Genentech Inc Métodos de diagnóstico y terapéuticos para el cáncer.
KR102350221B1 (ko) 2018-03-22 2022-01-14 스미또모 덴꼬오 하드메탈 가부시끼가이샤 표면 피복 절삭 공구 및 그 제조 방법
EP3861137A4 (en) * 2018-10-01 2022-07-13 Nantomics, LLC Evidence based selection of patients for clinical trials using histopathology
CN114072676B (zh) 2019-06-03 2024-07-12 法国国家卫生及研究医学协会 调节治疗方案的方法
WO2021092071A1 (en) 2019-11-07 2021-05-14 Oncxerna Therapeutics, Inc. Classification of tumor microenvironments
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
EP4172621A1 (en) 2020-06-30 2023-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies
JP7741831B2 (ja) 2020-06-30 2025-09-18 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 術前補助療法及び根治手術後の固形がんを患っている患者の再発及び／又は死亡のリスクを予測するための方法
US20250035635A1 (en) 2022-03-17 2025-01-30 Institut National De La Sante Et De La Recherche Medicale Methods for predicting response to an immunotherapeutic treatment in a patient with a cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4888278A (en) 1985-10-22 1989-12-19 University Of Massachusetts Medical Center In-situ hybridization to detect nucleic acid sequences in morphologically intact cells
US5447841A (en) 1986-01-16 1995-09-05 The Regents Of The Univ. Of California Methods for chromosome-specific staining
US6280929B1 (en) 1986-01-16 2001-08-28 The Regents Of The University Of California Method of detecting genetic translocations identified with chromosomal abnormalities
US5427932A (en) 1991-04-09 1995-06-27 Reagents Of The University Of California Repeat sequence chromosome specific nucleic acid probes and methods of preparing and using
US5472842A (en) 1993-10-06 1995-12-05 The Regents Of The University Of California Detection of amplified or deleted chromosomal regions
US6942970B2 (en) 2000-09-14 2005-09-13 Zymed Laboratories, Inc. Identifying subjects suitable for topoisomerase II inhibitor treatment
JP2002363169A (ja) * 2001-06-08 2002-12-18 Fujiyakuhin Co Ltd 抗腫瘍活性を有する複素環化合物
US7711492B2 (en) * 2003-09-03 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Methods for diagnosing lymphoma types
US20110152115A1 (en) * 2003-09-03 2011-06-23 The United States of America, as represented by the Secretary, Department of Health and Methods for identifying, diagnosing, and predicting survival of lymphomas
EP1893241A2 (en) 2005-04-28 2008-03-05 Ventana Medical Systems, Inc. Fluorescent nanoparticles conjugated to antibodies via a peg linker
US20060246523A1 (en) 2005-04-28 2006-11-02 Christopher Bieniarz Antibody conjugates
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
CN104090095B (zh) 2005-11-23 2016-06-01 文塔纳医疗系统公司 分子缀合物
US20110070582A1 (en) * 2008-11-03 2011-03-24 Source Precision Medicine, Inc. d/b/d Source MDX Gene Expression Profiling for Predicting the Response to Immunotherapy and/or the Survivability of Melanoma Subjects
ES2816625T3 (es) * 2010-09-24 2021-04-05 Niels Grabe Medios y métodos para la predicción de la respuesta a un tratamiento de un paciente con cáncer
EP2663650B1 (en) * 2011-01-11 2016-11-09 INSERM - Institut National de la Santé et de la Recherche Médicale Methods for predicting the outcome of a cancer in a patient by analysing gene expression

Also Published As

Publication number Publication date
EP3470531A1 (en) 2019-04-17
JP2019176880A (ja) 2019-10-17
LT2880180T (lt) 2019-01-25
TR201819211T4 (tr) 2019-01-21
WO2014023706A1 (en) 2014-02-13
US20150218650A1 (en) 2015-08-06
AU2013301609A1 (en) 2015-02-26
AU2013301609B2 (en) 2019-03-14
CA2881389A1 (en) 2014-02-13
ES2702722T3 (es) 2019-03-05
PT2880180T (pt) 2018-12-27
EP2880180A1 (en) 2015-06-10
JP6559566B2 (ja) 2019-08-14
PL2880180T3 (pl) 2019-04-30
DK2880180T3 (en) 2019-01-14
EP2880180B1 (en) 2018-10-03
JP2015530877A (ja) 2015-10-29
JP6995091B2 (ja) 2022-01-14
SG11201500922RA (en) 2015-04-29
US20200299784A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
HK1208624A1 (en) Methods for treating or predicting risk of a ventricular tachyarrhythmia event
WO2017049251A3 (en) Therapeutic cd47 antibodies
JP2015530877A5 (enExample)
EP4234711A3 (en) Methods and materials for assessing homologous recombination deficiency
WO2018074758A3 (ko) 면역질환 치료를 위한 고효능 줄기세포 선별방법
MX2023002251A (es) Antagonistas de union al eje pd-l1 y usos de los mismos para el tratamiento de cancer.
EP4524569A3 (en) Methods, compositions and devices for treating cancer with illudofulvenes
NZ621733A (en) Lung cancer biomarkers and uses thereof
GB2427468A (en) Devices and methods for enrichment and alteration of circulating tumour cells and other particles
WO2011135194A3 (en) Method for diagnosing risk of type 1 diabetes and for preventing onset of type 1 diabetes
EP3791944A3 (en) Water ride
WO2014081944A9 (en) Egfr and c-met-fibronectin type iii domain binding molecules
WO2020198370A3 (en) Therapeutic cd47 antibodies
ZA202100296B (en) Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
WO2015094996A3 (en) Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists
BR112017010078A2 (pt) composições, dispositivos e métodos de teste de sensibilidade de ibs
MY169230A (en) Nutritional composition containing a peptide component with adiponectin simulating properties and uses thereof
MX2023005293A (es) Composiciones, dispositivos y metodos de prueba de sensibilidad a la depresion.
GB2552271A (en) A method for diagnosing lung cancer
WO2005058251A3 (en) Hla-dr-specific antibodies, compositions and methods
EP4116713A3 (en) Compositions, devices, and methods of osteoarthritis sensitivity testing
MX2024000466A (es) Composiciones, dispositivos y metodos de pruebas de sensibilidad a la enfermedad de crohn.
MX2018011166A (es) Composiciones, dispositivos y metodos de prueba de sensibilidad de fibromialgia.
MX2013012648A (es) Metodo para determinar hipoxia clinicamente relevante en cancer.
WO2019066617A3 (ko) 항 c-met 항체 및 이의 용도

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180718

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240726

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241217

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241217

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251212

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260326

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260713